Description and Brand Names
Drug information provided by: Merative, Micromedex®
US Brand Name
- Breyanzi
Descriptions
Lisocabtagene maraleucel injection is used to treat large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B that has come back (relapsed) or did not respond to the treatment (refractory) in patients who have received at least 2 previous treatments that did not work well.
Lisocabtagene maraleucel injection is also used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least 2 types of cancer treatment (eg, BTK inhibitor, BCL-2 inhibitor) that did not work well.
Lisocabtagene maraleucel injection is also used to treat follicular lymphoma (FL) that has come back (relapsed) or did not respond to the treatment (refractory) in patients who have received at least 2 prior treatments.
Lisocabtagene maraleucel is an antineoplastic (cancer) medicine that is made from your own white blood cells, which have been modified to recognize and attack your cancer cells. Before you begin treatment, talk to your doctor about the benefits of this medicine as well as the possible risks of receiving it.
This medicine is available only under a restricted distribution program called Breyanzi® REMS (Risk Evaluation and Mitigation Strategy) Program.
This product is available in the following dosage forms:
Portions of this document last updated: July 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.